An Observational Study of BOTOX® for the Management of Urinary Incontinence in Patients With Idiopathic Overactive Bladder (GRACE)

Allergan

Status: Completed

Conditions: Urinary Bladder, Overactive; Urinary Incontinence

Treatments: Biological: botulinum toxin Type A

Study type: Observational

Funder types: Industry

Identifiers

NCT02161159

MAF/AGN/NS/OAB/002

Details and patient eligibility

About

This study will evaluate real world pattern of use of BOTOX® in actual clinical practice in patients with idiopathic overactive bladder (iOAB) with urinary incontinence whose symptoms have not been adequately managed by oral anticholinergic therapy.

Enrollment: 515 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• No prior treatment with botulinum toxin Type A for treatment of iOAB

Exclusion criteria

• Treatment with any botulinum toxin Type A within 18 months

Trial design

515 participants in 1 patient group

Patients With Urinary Incontinence Due to iOAB

Description:

Patients with urinary incontinence due to iOAB treated with BOTOX® in accordance with physician standard practice.

Treatment:

Biological: botulinum toxin Type A